Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results.
OBJECTIVE
The small number of boys present in most studies on final height (FH) after gonadotropin-releasing hormone agonist (GnRHa) treatment for central precocious puberty (CPP) offers difficulties in the evaluation of the effects of treatment on FH in males.


METHODS
We therefore combined FH data from The Netherlands, Italy and France to study the effect of GnRHa treatment in a large group of 26 boys with CPP.


RESULTS
The mean chronological age at the start of treatment was 7.6 +/- 2.0 (SD) years, bone age (BA) was 11.0 +/- 2.1 years. All boys were treated with depot formulations of the GnRHa triptorelin with established gonadal suppression for a mean treatment period of 4.7 +/- 2.1 years. FH was 172.9 +/- 6.6 cm. FH standard deviation score (SDS) was -0.66 +/- 1.22, not significantly different from the target height SDS of -0.23 +/- 0.75. FH-SDS was significantly lower in the subgroup of 12 patients with organic CPP compared to patients with idiopathic CPP (-1.34 +/- 1.06 vs. -0.08 +/- 1.06, respectively; p = 0.01), but no difference in height gain was observed. The mean estimated height gain, defined as the difference between predicted and actual adult height was 6.2 +/- 8.7 cm using the average tables of Bayley and Pinneau, and 0.3 +/- 8.6 cm using the BA advance adjusted tables. Regional differences in height gain were observed between the different countries, reflecting different local practices.


CONCLUSIONS
We conclude that GnRHa treatment in boys results in a FH close to target height.
Mul
D
D
Subdivision Endocrinology, Erasmus University Centre/Sophia Children's Hospital, Rotterdam, The Netherlands. Mul@alkg.azr.nl
Bertelloni
S
S
Carel
J C
JC
Saggese
G
G
Chaussain
J L
JL
Oostdijk
W
W
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001827:Body Height / Q000187:drug effects*; D002648:Child; D005602:France; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007558:Italy; D008297:Male; D009426:Netherlands; D011629:Puberty, Precocious / Q000188:drug therapy*; D012189:Retrospective Studies; D017329:Triptorelin Pamoate / Q000008:administration & dosage
D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone